8-K/A: ZimVie Completes Sale of Spine Business to H.I.G. Capital, Provides Pro Forma Financials

ZimVie Inc. has finalized the sale of its spine business to H.I.G. Capital for $315 million in cash and a $60 million promissory note, and has released pro forma financial information reflecting the transaction.

Summary

• ZimVie Inc. completed the sale of its spine business to an affiliate of H.I.G. Capital on April 1, 2024.
• The sale included $315 million in cash, subject to adjustments, and a $60 million promissory note.
• The company used $275 million of the proceeds to repay outstanding debt.
• The pro forma balance sheet, as of December 31, 2023, reflects the impact of the sale and debt repayment.
• The sale of the spine business was already accounted for as discontinued operations in ZimVie's financial statements for the three years ended December 31, 2023.
• The pro forma balance sheet shows total assets of $773.3 million after the transaction, compared to $1,205.3 million before the sale.
• Total liabilities decreased to $355.7 million from $795.9 million.
• The company's cash and cash equivalents increased to $88.6 million after the transaction.

Sentiment

Score: 7

Explanation: The document reflects a significant strategic move for the company, with a positive impact on its cash position and debt levels. However, the loss of the spine business revenue is a negative factor. Overall, the sentiment is moderately positive.

Positives

• The sale of the spine business generated $315 million in cash and a $60 million promissory note.
• ZimVie reduced its outstanding debt by $275 million using the proceeds from the sale.
• The company's cash position improved to $88.6 million after the transaction.
• The promissory note will generate interest income for ZimVie.

Negatives

• The sale resulted in a significant reduction in total assets, from $1,205.3 million to $773.3 million.
• The company has lost the revenue and earnings from the divested spine business.

Risks

• The final cash amount from the sale is subject to adjustments based on the final working capital balance.
• The pro forma financial information is not necessarily indicative of future financial performance.
• The company will need to manage its operations without the revenue from the spine business.

Future Outlook

The company has not provided specific forward-looking statements in this document, but the pro forma financials provide a view of the company's financial position after the sale of the spine business.

Industry Context

The sale of the spine business is part of a strategic shift for ZimVie, focusing on other areas of its business. This type of divestiture is not uncommon in the medical device industry as companies look to streamline operations and focus on core competencies.

Comparison to Industry Standards

• The divestiture of a business unit is a common strategy in the medical device industry, similar to Medtronic's spin-off of its Covidien business.
• The use of proceeds to pay down debt is a typical move after a divestiture, similar to how Johnson & Johnson has managed its portfolio.
• The pro forma financials provide a clear picture of the company's financial position post-transaction, which is standard practice for such events.

Stakeholder Impact

• Shareholders will see a change in the company's financial structure and business focus.
• Employees in the divested spine business will transition to the new owner, H.I.G. Capital.
• Customers of the spine business will now be served by H.I.G. Capital.

Key Dates

Keywords

ZimVie, Spine Business, H.I.G. Capital, Divestiture, Pro Forma Financials, Debt Repayment, Promissory Note, Discontinued Operations